A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy

Transplantation

Volumn 64, Issue 7, 1997, Pages 999-1006

  Martin Wissing, K ^a   Morelon, Emmanuel ^b   Legendre, Christophe ^b   De Pauw, Luc ^a   Lebeaut, Alexandre ^c   Grint, Paul ^c   Maniscalki, Margaret ^c   Ickx, Brigitte ^a   Vereerstraeten, Pierre ^a   Chatenoud, Lucienne ^b   Kreis, Henri ^b   Goldman, Michel ^a   Abramowicz, Daniel ^a  

^a ERASME HOSPITAL   (Belgium)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOSUPPRESSIVE AGENT; OKT 3; PLACEBO; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; MALE; NEUROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIBODY FORMATION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEVER; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-8; KIDNEY TRANSPLANTATION; MALE; MUROMONAB-CD3; PILOT PROJECTS; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0343329759     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199710150-00012     Document Type: Article

References (53)

1. Kung P, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206: 347.
2. Ortho Muticenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985; 313: 337.
3. Norman DJ, Kahana L, Stuart FJ, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44.
4. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220.
5. Abramowicz D, Norman DJ, Vereerstraeten P, et al. OKT3 prophylaxis in renal grafts with prolonged ischemia times: association with improvement in long-term survival. Kidney Int 1996; 49: 768.
6. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2 and gamma interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
7. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320: 1420.
8. Peltz GA, Trounstine ML, Moore KW. Cloned and expressed human Fc receptor for IgG mediates anti-CD3-dependent lymphoproliferation. J Immunol 1988; 141: 1891.
9. Ceuppens JL, Van Vaeck F. Direct demonstration of binding of anti-Leu 4 antibody to the 40 kDa Fc receptor on monocytes as a prerequisite for anti-Leu 4-induced T cell mitogenesis. J Immunol 1987; 139: 4067.
10. Ferran C, Dautry F, Mérite S, et al. Anti-tumor necrosis factor modulates anti-CDS-triggered T cell cytokine gene expression in vivo. J Clin Invest 1994; 93: 2189.
11. Chatenoud L, Ferran C, Bach JF. The anti-CD3 induced syndrome: a consequence of massive in vivo cell activation. Curr Top Microbiol Immunol 1991; 174: 121.
12. Goldman M, Abramowicz D, De Pauw L, et al. OKT3-induced cytokine release attenuation by high-dose methylprednisolone. Lancet 1989; 2: 802.
13. Chatenoud L, Legendre C, Ferran C, Bach JF, Kreis H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome: dosage and kinetics prerequisites. Transplantation 1991; 51: 334.
14. Bemelman FJ, Buysmann S, Surachno J, Wilmink JM, Schellekens PTA, ten Berge IJM. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney Int 1994; 46: 1674.
15. Vincenti F, Danovitch GM, Neylan JF, Steiner R, Everson MP, Gaston RS. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3: a randomized, double-blind, placebo-controlled study. Transplantation 1996; 61: 573.
16. Shield CF, Kahana L, Pirsch J, et al. Use of indomethacin to minimize the adverse reactions associated with orthoclone OKT3 treatment of kidney allograft rejection. Transplantation 1992; 54: 164.
17. Chan G, Weinstein S, Wright C, et al. Encephalopathy associated with OKT3 administration: possible interactions with indomethacin. Transplantation 1991; 52: 148.
18. Richard EA, Lorber MI, Marks WH, Bia MJ. Are calcium channel blockers protective against first-dose reactions to OKT3? Transplantation 1992; 54: 372.
19. Eason JD, Pascual M, Wee S, et al. Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome. Transplantation 1996; 61: 224.
20. Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992; 54: 997.
21. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444.
22. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209.
23. de Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915.
24. Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992; 148: 3133.
25. Taga K, Tosato G. IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol 1992; 148: 1143.
26. de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells: specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754.
27. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood 1993; 81: 2964.
28. Schandene L, Gerard C, Crusiaux A, Abramowicz D, Velu T, Goldman M. Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline in renal transplant recipients. Transplant Proc 1993; 25: 55.
29. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory cytokine production and immune responses. J Immunol 1995; 154: 5492.
30. Huhn RD, Radwanski E, O'Connell SM, et al. Pharmacokinetics and immunomodulatory properties of intravenously administered recombinant human interleukin-10 in healthy volunteers. Blood 1996; 87: 699.
31. Pajkrt D, Camoglio L, Tiel-van Buul MCM, et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia. J Immunol 1997; 158: 3971.
32. Donckier V, Flament V, Gerard C, et al. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10. Transplantation 1994; 57: 1436.
33. Wissing M, Donckier V, Delvaux A, et al. Effects of interleukin-10 on the immunoactivating and immunosuppressive properties of anti-CD3 monoclonal antibody. Transplant Proc 1994; 26: 3167.
34. Doutrelepont JM, Abramowicz D, Borre B, et al. Prophylactic OKT3: practical considerations for the prevention of first dose reactions. Transplant Proc 1993; 25 (suppl. 1): 39.
35. Burdin N, Van Kooten C, Galibert L, et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol 1995; 154: 2533.
36. Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J Immunol 1995; 154: 4341.
37. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342-1514.
38. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207.
39. Abramowicz D, Pradier O, Crusiaux A, et al. The systemic release of IL-10 after OKT3 administration to kidney transplant recipients might mitigate OKT3 toxicity [Abstract]. J Am Soc Nephrol 1994; 5: 977.
40. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histological diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
41. Chiu PJS, Radwanski E, Tetiloff G, Monge A, Swanson SJ. Interleukin-10 pharmacokinetics in intact and nephrectomized mice. Eur Cytokine Netw 1996; 7: 67.
42. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin-10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179: 1695.
43. Carson WE, Lindemann MJ, Baiocchi R, et al. The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995; 85: 3577.
44. Sironi M, Munoz C, Pollicino T, et al. Divergent effects of interleukin-10 on cytokine production by mononuclear phagocytes and endothelial cells. Eur J Immunol 1993; 23: 2692.
45. Seitz M, Loetscher P, Dewald B, Towbin H, Gallati H, Baggiolini M. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995; 25: 1129.
46. Marchant A, Alegre ML, Hakim A, et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995; 15: 266.
47. Lowry RP, Konieczny B, Alexander D, et al. Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice. Transplant Proc 1995; 27: 186.
48. Gorczynski RM, Wojcik D. A role for nonspecific (cyclosporin A) or specific (monoclonal antibodies to ICAM-1, LFA-1, and IL-10) immunomodulation in the prolongation of skin allografts after antigen-specific pretransplant immunization or transfusion. J Immunol 1994; 152: 2011.
49. Delvaux A, Donckier V, Bruyns C, et al. Effects of systemic administration of rIL-10 in an in vivo model of alloreactivity. Transplantation 1994; 58: 972.
50. Lee MS, Wogensen L, Shizuru J, Oldstone MBA, Sarvetnik N. Pancreatic islet production of murine interleukin-10 does not inhibit immune mediated tissue destruction. J Clin Invest 1994; 93: 1332.
51. Zheng XX, Steele AW, Nickerson PW, Steurer W, Steiger J, Strom TB. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 1995; 154: 5590.
52. Qian S, Li W, Li Y, et al. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation 1996; 62: 1709.
53. Xu G, Sharma VK, Li B, et al. Intragraft expression of IL-10 messanger RNA: a novel correlate of renal allograft rejection. Kidney Int 1995; 48: 1504.